OncoNano Medicine, Inc. today announced it will be presenting data on two development candidates, as well as its ON-BOARD™ delivery platform, at the 37th Annual Meeting of the Society for Immunology of Cancer (SITC), taking place November 8-12, 2022 in Boston, Massachusetts.
SOUTHLAKE, Texas--(BUSINESS WIRE)-- OncoNano Medicine, Inc. today announced it will be presenting data on two development candidates, as well as its ON-BOARD™ delivery platform, at the 37th Annual Meeting of the Society for Immunology of Cancer (SITC), taking place November 8-12, 2022 in Boston, Massachusetts.
An oral and poster presentation by Dr. Qiang Feng detail new pre-clinical data for ONM-405, an IL-2-Fc construct formulated with OncoNano’s proprietary ON-BOARD™ polymeric-micelle delivery system. OncoNano’s lead clinical candidate, pegsitacianine, currently in Phase 2 clinical trials, is formulated with ON-BOARD™. The ON-BOARD™ platform is designed to carry oncology intervention payloads systemically to the tumor microenvironment, minimizing systemic exposure and toxicity.
OncoNano will also present a poster detailing data from studies involving the use of the ON-BOARD™ platform for encapsulation and delivery of bispecific T cell engagers. In addition, a poster will feature new preclinical data of ONM-501, a novel dual-activating polyvalent STING (STimulator of INterferon Genes) agonist for immuno-oncology applications.
Presentations Overview
| Title: | Ultra-pH Sensitive Nanoparticles Increase Therapeutic Index of IL-2-Fc | |
| Presenter: | Dr. Qiang Feng, Postdoctoral Fellow, Jinming Gao Lab, UT Southwestern Medical Center | |
| Date: | November 12, 2022 | |
| Time: | 10:40 am – 10:50 am EST | |
| Location: | Session 302: Thomas Waldmann Memorial Plenary Session: New Immunotherapies, Boston Convention and Exhibition Center, Boston, MA | |
|
|
| |
| Title: | ONM-501, a Polyvalent STING Agonist, Exhibits Anti-Tumor Efficacy with Increased Tumor T-Cell Infiltration in Mice and is Well Tolerated in Rats and Non-Human Primates | |
| Date: | November 10 – 11, 2022 | |
| Time: | 9:00 am - 9:00 pm EST | |
| Location: | Poster Hall, Boston Convention and Exhibition Center, Boston, MA | |
|
|
| |
| Title: | A Clinically Validated pH-Sensitive Nanomedicine Platform for Encapsulating Therapeutic Bispecific T cell engagers for Tumor Specific Delivery and Activation | |
| Date: | November 10 – 11, 2022 | |
| Time: | 9:00 am - 9:00 pm EST | |
| Location: | Poster Hall, Boston Convention and Exhibition Center, Boston, MA |
About OncoNano Medicine
OncoNano Medicine is developing a new class of products that utilize principles of molecular cooperativity in their design to exploit pH as a biomarker to diagnose and treat cancer with high specificity. Our product candidates and interventions are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, agents for real-time image guided surgery and a platform of immune-oncology therapeutics that activate and guide the body’s immune system to target cancer.
OncoNano’s lead development candidate is pegsitacianine, a novel fluorescent nanoprobe using the ON-BOARD platform, that is currently under study in Phase 2 clinical trials as a real-time surgical imaging agent for use in multiple cancer surgeries. ONM-501, OncoNano’s second development program, is a next generation STING (STimulator of INterferon Genes) agonist that is advancing towards a first in human trial in the first half of 2023. Pegsitacianine and ONM-501 have been supported by grants received from the Cancer Prevention Research Institute of Texas. Learn more at www.OncoNano.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005254/en/
Source: OncoNano Medicine, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20221005005254/en
